Literature DB >> 1687629

Chemical restraint-reversal with medetomidine and atipamezole in veterinary small animal practice: a survey on the opinions of the dog owners and veterinarians.

T Vähä-Vahe1, P Niemi, J Tuominen.   

Abstract

The opinions of animal owners and practising veterinarians concerning a new restraint-reversal medication (medetomidine-atipamezole) for dogs were obtained by two questionnaires in connection with a clinical study. Four alternative answers to each statement question scored as "completely agree", "somewhat agree", "somewhat disagree" and "completely disagree". The questionnaires were completed by 21 veterinarians and 245 dog owners. The overall response to the treatment was clearly positive. Both groups had a favourable attitude towards drug use with mean combined scores (from 1 to 4; 4 = most favourable) of 48.1 (max 56) for the dog owners and 39.2 (max 52) for the veterinarians. Only a little information was gained about the background of negative sentiments. Some pet owners (19%) opposed to medication on a priori grounds, some (26%) reacted strongly to the dizziness of their animals and some owners (21%) complained because of general anxiety before, during and after their pets were treated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687629      PMCID: PMC8127926     

Source DB:  PubMed          Journal:  Acta Vet Scand        ISSN: 0044-605X            Impact factor:   1.695


  3 in total

1.  Clinical evaluation of medetomidine, a novel sedative and analgesic drug for dogs and cats.

Authors:  T Vähä-Vahe
Journal:  Acta Vet Scand       Date:  1989       Impact factor: 1.695

2.  Antagonism of xylazine sedation with yohimbine, 4-aminopyridine, and doxapram in dogs.

Authors:  R C Hatch; J V Kitzman; J M Zahner; J D Clark
Journal:  Am J Vet Res       Date:  1985-02       Impact factor: 1.156

3.  The clinical effectiveness of atipamezole as a medetomidine antagonist in the dog.

Authors:  A T Vähä-Vahe
Journal:  J Vet Pharmacol Ther       Date:  1990-06       Impact factor: 1.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.